MSANTD2

Across TCGA pan-cancer cohorts, MSANTD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MSANTD2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MSANTD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSANTD2 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

PDAC, GBM, and LUAD are the cancer types where MSANTD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.174	0.546	.008	11	view →
GBM	OS	Median	All	0.528	0.268	.003	6	view →
LUAD	OS	Median	II,III,IV	0.360	0.779	.010	6	view →
HNSC	OS	Median	All	0.840	0.617	.025	2	view →
LSCC	OS	Median	II,III,IV	1.000	0.810	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MSANTD2–PDAC (DFS)

Open the PDAC breakdown →